Liquidia (NASDAQ:LQDA) Insider Sells $16,800.12 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 276 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $60.87, for a total value of $16,800.12. Following the completion of the transaction, the insider owned 146,743 shares in the company, valued at $8,932,246.41. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sarah Krepp also recently made the following trade(s):

• On Monday, April 13th, Sarah Krepp sold 4,557 shares of Liquidia stock. The shares were sold at an average price of $38.37, for a total value of $174,852.09.

Liquidia Price Performance

Shares of Liquidia stock opened at $61.85 on Friday. The stock’s 50-day simple moving average is $46.78 and its 200-day simple moving average is $39.56. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $66.24. The company has a market capitalization of $5.50 billion, a price-to-earnings ratio of 441.82 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The firm’s revenue was up 4187.1% compared to the same quarter last year. As a group, analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on LQDA shares. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Raymond James Financial restated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday. BTIG Research boosted their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Needham & Company LLC boosted their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Wells Fargo & Company boosted their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $55.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Caprock Group LLC bought a new position in shares of Liquidia during the third quarter valued at approximately $37,114,000. Apis Capital Advisors LLC bought a new position in shares of Liquidia during the third quarter valued at approximately $9,569,000. Farallon Capital Management LLC grew its stake in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new position in shares of Liquidia during the third quarter valued at approximately $1,536,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).